2672 studies found for:    non-Hodgkin's lymphoma
Show Display Options
RSS Create an RSS feed from your search for:
non-Hodgkin's lymphoma
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Bendamustine;   Drug: Rituximab
2 Completed Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab
3 Completed Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
4 Completed SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bendamustine and rituximab
5 Active, not recruiting A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Everolmus
6 Completed
Has Results
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Oxaliplatin
7 Not yet recruiting A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Condition: Relapsed/Refractory Non-Hodgkin's Lymphoma
Intervention: Drug: [14C]ABT-199 (GDC-0199)
8 Active, not recruiting Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Dasatinib
9 Completed Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Zevalin-BuCyE
10 Recruiting Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Condition: Indolent Non-Hodgkin's Lymphoma
Interventions: Biological: Arm A: Rituximab;   Biological: Arm B: GA101
11 Recruiting Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: LBH589
12 Terminated Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors
Conditions: Non-Hodgkin's Lymphoma,;   Solid Tumors
Intervention: Drug: PPI-2458
13 Completed Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: Motexafin gadolinium
14 Recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
15 Enrolling by invitation An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: ABT-199
16 Completed Treatment for Subjects With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: pegfilgrastim;   Drug: Filgrastim
17 Terminated Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Advanced Solid Tumors;   Non-Hodgkin's Lymphoma
Intervention: Drug: RH-1
18 Completed A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma
Interventions: Drug: SyB L-0501;   Drug: Rituximab
19 Unknown  Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )
20 Completed
Has Results
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bortezomib + Rituximab;   Drug: Rituximab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years